Publications by authors named "Hidetsugu Takahashi"
Article Synopsis
- The study evaluated the effectiveness and safety of three androgen receptor pathway inhibitors (ARPI) — abiraterone, enzalutamide, and apalutamide — in treating patients with metastatic hormone-sensitive prostate cancer in a real-world setting.
- Records of 668 high-risk patients treated with these drugs were analyzed, comparing prostate-specific antigen (PSA) responses, overall survival, and the incidence of adverse events.
- Results showed no significant differences in overall survival or cancer-specific survival among the three drugs, although abiraterone demonstrated a higher rate of achieving a 99% PSA decline, and enzalutamide had the lowest treatment discontinuation rates.
Article Synopsis
- Androgen receptor signaling inhibitors (ARSIs) have significantly improved the treatment of metastatic castration-sensitive prostate cancer (mCSPC) by influencing prostate-specific antigen (PSA) dynamics, which are critical for assessing disease control.
- A retrospective study involving 552 mCSPC patients was conducted to analyze the impact of PSA nadir, PSA response rate, and time to PSA nadir on oncological outcomes like cancer-specific survival and overall survival.
- Results indicated that achieving a low PSA nadir (≤ 0.02 ng/mL) and a high PSA response rate (≥ 99%) were strong independent predictors of better clinical outcomes, underscoring the importance of monitoring PSA dynamics in patient treatment.
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
Fumihiko Urabe Katsuki Muramoto Takafumi Yanagisawa Wataru Fukuokaya Keiichiro Mori Hidetsugu Takahashi
Int J Urol
November 2024
Article Synopsis
- - A study investigated the treatment outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) after the approval of upfront androgen receptor signaling inhibitors (ARSIs) from 2018 to 2023.
- - Researchers analyzed data from 829 patients, finding that those treated with ARSIs alongside hormone therapy had better survival times and lower rates of resistance compared to those on combined hormone blockade (CAB).
- - Despite fewer serious side effects with CAB, the study suggests that ARSIs with hormone therapy should be the preferred first-line treatment due to their improved oncological outcomes.
Objectives: This study explored the impacts of peri-operative changes in the neutrophil-to-lymphocyte ratio (NLR) on the survival rate after radical nephroureterectomy.
Methods: This retrospective analysis included a multicentric cohort of patients diagnosed with upper tract urothelial carcinoma (UTUC) who had undergone radical nephroureterectomy from 2012 to 2021. We assessed the preoperative NLR, postoperative NLR, delta-NLR (difference between postoperative and preoperative NLRs), and NLR change (ratio of postoperative to preoperative NLR).